ArticleHuman vaccines & immunotherapeutics2023
Changing patterns of invasive meningococcal disease and future immunization strategies.
Article in Human vaccines & immunotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study.Human vaccines & immunotherapeutics · 2026Trial
- Immunogenicity, Reactogenicity, and Safety of a Pentavalent Meningococcal ABCWY Vaccine in Adolescents and Young Adults Who Had Previously Received a Meningococcal ACWY Vaccine: A Phase 3, Randomized Controlled Clinical Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Trial
- Immune persistence and booster response of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) 5 years after primary vaccination of adults at ≥56 years of age.Human vaccines & immunotherapeutics · 2024Trial
- Burden of Invasive Meningococcal Disease: Evolving Epidemiology and Implications for Prevention Policy.Infectious diseases and therapy · 2026Review
- Meningococcal Disease in Older Adults: Challenges in Diagnosis and Management.Infectious diseases and therapy · 2026Review
- Invasive meningococcal disease in adolescents in Europe and select geographies: Disease burden, unmet medical need, and optimizing prevention.Human vaccines & immunotherapeutics · 2025Review
- Joint consensus on reducing the burden of invasive meningococcal disease in the Asia-Pacific region.Human vaccines & immunotherapeutics · 2025Review
- Invasive Meningococcal Disease-Changes in Epidemiologic Trends and Outcome over 24 Years in a Tertiary Care Hospital from Romania.Pathogens (Basel, Switzerland) · 2025Article
- Need for Invasive Meningococcal Disease Prevention Through Vaccination for Young Children in the Americas.Vaccines · 2025Review
- Outer Membrane Vesicles as a Versatile Platform for Vaccine Development: Engineering Strategies, Applications and Challenges.Journal of extracellular vesicles · 2025Review
- Review
- 4CMenB journey to the 10-year anniversary and beyond.Human vaccines & immunotherapeutics · 2024Review
- Review
- Invasive meningococcal disease in older adults: current perspectives and call for action.European geriatric medicine · 2024Review
- Invasive Disease Due toMicroorganisms · 2023Article
- Nasopharyngeal Meningococcal Carriage among Older Adults in Türkiye (MeninGOLD Study).Microorganisms · 2023Article
- Meningococcal burden of disease in Argentina: 10 years epidemiologic review.Human vaccines & immunotherapeutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive meningococcal disease (IMD) is a life-threatening disease caused by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.